Generate Biomedicines GENB Institutional Ownership

Updated Oct 10, 2026

Generate Biomedicines, Inc. (NASDAQ:GENB) was held by 87 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Together they owned 78.00% of the outstanding stock in Q2 2026, up from 72.17% a quarter earlier.
• Shares of GENB held in total rose 8.14% from Q1 2026.
• Of the 87 holders, 67 added to their positions, 10 reduced their stakes and 10 left their positions unchanged in Q2 2026.
• Institutional investors held 100.05Mn shares of Generate Biomedicines in total at the end of Q2 2026, up 7.53Mn from the prior quarter.
• As of June 30, 2026, the biggest holder of Generate Biomedicines was Flagship Pioneering, LLC with 62.67Mn shares, or 48.86% of shares outstanding.
• Holders that added the most shares of Generate Biomedicines in Q2 2026 were FMR LLC (+1Mn shares), Vanguard Capital Management LLC (+1Mn shares), ARK Investment Management LLC (+786.21K shares), Geode Capital Management, LLC (+616.76K shares) and Davern Capital Partners, LP (+232.88K shares).
• The biggest cuts to GENB positions during Q2 2026 came from JPMorgan Chase & Co (-1.54Mn shares), Millennium Management LLC (-354.97K shares), Braidwell LP (-309.15K shares), Goldman Sachs Group Inc (-159.51K shares) and CenterBook Partners LP (-135.25K shares).
• According to Business Quant data, the leading holders of GENB for Q2 2026 were Flagship Pioneering, LLC (62.67Mn shares), FMR LLC (5.22Mn shares), Capital World Investors (4.22Mn shares), Braidwell LP (3.28Mn shares), T. Rowe Price Associates Inc (2.16Mn shares), Norges Bank (2.09Mn shares), ARCH Venture Management, LLC (1.94Mn shares), Harbourvest Partners LLC (1.72Mn shares), BlackRock, Inc. (1.66Mn shares) and Baker Bros. Advisors LP (1.42Mn shares).